Diagnostic and prognostic role of galectin 3 expression in cutaneous melanoma

Simple item page
dc.AffiliationOctober University for modern sciences and Arts (MSA)
dc.contributor.authorAbdou A.G.
dc.contributor.authorHammam M.A.
dc.contributor.authorFarargy S.E.
dc.contributor.authorFarag A.G.A.
dc.contributor.authorEl Shafey E.N.
dc.contributor.authorFarouk S.
dc.contributor.authorElnaidany N.F.
dc.contributor.otherPathology Department
dc.contributor.otherMenofiya University
dc.contributor.otherShebein Elkom
dc.contributor.otherAhmed Maher Educational Hospital
dc.contributor.otherCairo
dc.contributor.otherEgypt; Dermatology and Andrology Department
dc.contributor.otherMenofiya University
dc.contributor.otherShebein Elkom
dc.contributor.otherAhmed Maher Educational Hospital
dc.contributor.otherCairo
dc.contributor.otherEgypt; Faculty of Medicine
dc.contributor.otherMenofiya University
dc.contributor.otherShebein Elkom
dc.contributor.otherAhmed Maher Educational Hospital
dc.contributor.otherCairo
dc.contributor.otherEgypt; Clinical Pharmacy Department
dc.contributor.otherFaculty of Pharmacy
dc.contributor.otherMSA University
dc.contributor.otherOctober City
dc.contributor.otherEgypt
dc.date.accessioned2020-01-25T19:58:32Z
dc.date.available2020-01-25T19:58:32Z
dc.date.issued2010
dc.descriptionScopus
dc.description.abstractMany of the histopathologic criteria used to diagnose melanoma overlap with atypical but otherwise benign naevi such as dysplastic or Spitz naevi. Galectin-3 is a member of the galectin gene family and is expressed at elevated levels in a variety of neoplastic cell types. The aim of the present study was to investigate the diagnostic value of galectin-3 expression compared with homatropine methyle bromide-45(HMB-45) (one of the established and widely used immunohistochemical melanocytic markers) together with assessment of its prognostic value in melanoma lesions. This study was carried out on 21 cases of melanoma and 20 benign pigmented naevi. Galectin-3 was expressed in all the examined benign and malignant melanocytic lesions. The nucleocytoplasmic pattern of galectin-3 appeared in malignant cases only with 42.86% sensitivity, 100% specificity, and 70.73% accuracy. This pattern tended to be associated with thick melanoma (P = 0.08) and reduced survival (P = 0.22). The intensity of galectin-3 assessed by H-score was significantly of higher values in malignant lesions compared with benign lesions (P < 0.0001). The best cut-off value for discrimination between benign and malignant melanocytic lesions was 295 with 95% sensitivity, 70% specificity, and 83% accuracy. The diagnostic power of galectin-3 in distinguishing between benign and malignant melanocytic lesions relies on the pattern and the intensity of its expression. The nucleocytoplasmic pattern of galectin-3 expression carries greater probability of a malignant phenotype and a poor prognostic impact on patients' outcome. Copyright � 2010 by Lippincott Williams & Wilkins.en_US
dc.description.urihttps://www.scimagojr.com/journalsearch.php?q=27047&tip=sid&clean=0
dc.identifier.doihttps://doi.org/10.1097/DAD.0b013e3181e02f29
dc.identifier.doiPubMed ID 20885286
dc.identifier.issn1931091
dc.identifier.otherhttps://doi.org/10.1097/DAD.0b013e3181e02f29
dc.identifier.otherPubMed ID 20885286
dc.identifier.urihttps://t.ly/EXewB
dc.language.isoEnglishen_US
dc.relation.ispartofseriesAmerican Journal of Dermatopathology
dc.relation.ispartofseries32
dc.subjectdiagnosisen_US
dc.subjectgalectin-3en_US
dc.subjectHMB-45en_US
dc.subjectmelanomaen_US
dc.subjectprognosisen_US
dc.subjectgalectin 3en_US
dc.subjecthomatropine methyl bromideen_US
dc.subjectadulten_US
dc.subjectageden_US
dc.subjectarticleen_US
dc.subjectcancer diagnosisen_US
dc.subjectcancer survivalen_US
dc.subjectclinical articleen_US
dc.subjectclinical assessmenten_US
dc.subjectcontrolled studyen_US
dc.subjectdiagnostic accuracyen_US
dc.subjectfemaleen_US
dc.subjecthumanen_US
dc.subjecthuman tissueen_US
dc.subjectimmunohistochemistryen_US
dc.subjectmaleen_US
dc.subjectmelanomaen_US
dc.subjectnevusen_US
dc.subjectpriority journalen_US
dc.subjectprognosisen_US
dc.subjectprotein expressionen_US
dc.subjectsensitivity and specificityen_US
dc.subjectAdulten_US
dc.subjectAgeden_US
dc.subjectAged, 80 and overen_US
dc.subjectDiagnosis, Differentialen_US
dc.subjectEgypten_US
dc.subjectFemaleen_US
dc.subjectGalectin 3en_US
dc.subjectHumansen_US
dc.subjectImmunohistochemistryen_US
dc.subjectMaleen_US
dc.subjectMelanocytesen_US
dc.subjectMelanomaen_US
dc.subjectMiddle Ageden_US
dc.subjectNevus, Pigmenteden_US
dc.subjectPredictive Value of Testsen_US
dc.subjectPrognosisen_US
dc.subjectProportional Hazards Modelsen_US
dc.subjectSensitivity and Specificityen_US
dc.subjectSkin Neoplasmsen_US
dc.subjectSurvival Analysisen_US
dc.subjectTropanesen_US
dc.subjectTumor Markers, Biologicalen_US
dc.subjectYoung Adulten_US
dc.titleDiagnostic and prognostic role of galectin 3 expression in cutaneous melanomaen_US
dc.typeArticleen_US
dcterms.isReferencedByEl-Bolkainy, M.N., Nouh, M.A., El-Bolkainy, T.N., Skin Tumors (Malignant Melanoma) in Topographic Pathology of Cancer. 3rd edn (2005) Egypt: National Cancer Institute Cairo University, pp. 128-131; Mokhtar, N., Gouda, I., Adel, I., Malignant skin tumors (2007) Cancer Pathology Registry 2003-2004 and Time Trend Analysis, pp. 83-85. , Mokhtar N, Gouda I, Adel I, eds Cairo: NCI, El Sheraa Press; Farmer, E.R., Gonin, R., Hanna, M.P., Discordance in the histopathologic diagnosis of melanoma and melanocytic nevi between expert pathologists (1996) Hum Pathol., 27, pp. 528-531; Kashani-Sabet, M., Rangel, J., Torabian, S., A multi-marker assay to distinguish malignant melanomas from benign nevi (2009) Proc Natl Acad Sci USA., 14, pp. 6268-6272; Park, Y.J., Kwak, S.H., Kim, D.C., Diagnostic value of galectin-3, HBME-1, cytokeratin 19, high molecular weight cytokeratin, cyclin D1 and p27(kip1) in the differential diagnosis of thyroid nodules (2007) J Korean Med Sci., 22, pp. 621-628; Chun-Sheng, C., Wei-Guo, D., He-Sheng, L., Expression of galectin-3 in gastric carcinoma and its significance (2004) Chinese J Cancer Res., 3, pp. 176-181; Endo, K., Kohnoe, S., Tsujita, E., Galectin-3 expression is a potent prognostic marker in colorectal cancer (2005) Anticancer Res., 25, pp. 3117-3121; Matsuda, Y., Yamagiwa, Y., Fukushima, K., Expression of galectin-3 involved in prognosis of patients with hepatocellular carcinoma (2008) Hepatol Res., 38, pp. 1098-1111; Kim, S.J., Lee, S.J., Sung, H.J., Increased serum 90K and Galectin-3 expression are associated with advanced stage and a worse prognosis in diffuse large B-cell lymphomas (2008) Acta Haematol., 120, pp. 211-216; Khan, M.S., Dodson, A.R., Heatley, M.K., Ki-67, oestrogen receptor, and progesterone receptor proteins in the human rete ovarii and in endometriosis (1999) J Clin Pathol., 52, pp. 517-520; Achilles, E., Schroder, S., Positive cytokeratin results in malignant melanoma. Pitfall in differential immunohistological diagnosis of occult neoplasms (1994) Pathologe., 15, pp. 235-241; Pag�s, C., Rochaix, P., Al Saati, T., KBA.62: A useful marker for primary and metastatic melanomas (2008) Hum Pathol., 39, pp. 1136-1142; Prieto, V.G., Shea, C.R., Use of immunohistochemistry in melanocytic lesions (2008) J Cutan Pathol., 35 (S2), pp. 1-10; Kapur, R.P., Bigler, S.A., Skelly, M., Anti-melanoma monoclonal antibody HMB45 identifies an oncofetal glycoconjugate associated with immature melanosomes (1992) J Histochem Cytochem., 40, pp. 207-212; Kucher, C., Zhang, P.J., Pasha, T., Expression of Melan-A and Ki-67 in desmoplastic melanoma and desmoplastic nevi (2004) Am J Dermatopathol., 26, pp. 452-457; Fullen, D.R., Reed, J.A., Finnerty, B., S100A6 preferentially labels type C nevus cells and nevic corpuscles: Additional support for Schwannian differentiation of intradermal nevi (2001) J Cutan Pathol., 28, pp. 393-399; Busam, K.J., Chen, Y.T., Old, L.J., Expression of melan-A (MART1) in benign melanocytic nevi and primary cutaneous malignant melanoma (1998) Am J Surg Pathol., 22, pp. 976-982; Sheffield, M.V., Yee, H., Dorvault, C.C., Comparison of five antibodies as markers in the diagnosis of melanoma in cytologic preparations (2002) Am J Clin Pathol., 118, pp. 930-936; Kikuchi, A., Shimizu, H., Nishikawa, T., Expression and ultrastructural localization of HMB-45 antigen (1996) Br J Dermatol., 135, pp. 400-405; Xu, X., Chu, A.Y., Pasha, T.L., Immunoprofile of MITF, tyrosinase, melan-A, and MAGE-1 in HMB45-negative melanomas (2002) Am J Surg Pathol., 26, pp. 82-87; Yu, C.H., Chen, H.H., Liu, C.M., HMB-45 may be a more sensitive maker than S-100 or Melan-A for immunohistochemical diagnosis of primary oral and nasal mucosal melanomas (2005) J Oral Pathol Med., 34, pp. 540-545; Roy, S., Dhingra, K., Mandal, S., Khurana, N., Unusual presentation of metastatic amelanotic melanoma of unknown primary origin as a solitary breast lump (2008) Melanoma Res., 18, pp. 447-450; Hubert, M., Wang, S.Y., Wang, J.L., Intranuclear distribution of galectin-3 in mouse 3T3 fibroblasts: Comparative analyses by immunofluorescence and immunoelectron microscopy (1995) Exp Cell Res., 220, pp. 397-406; Prieto, V.G., Mourad-Zeidan, A.A., Melnikova, V., Galectin-3 expression is associated with tumor progression and pattern of sun exposure in melanoma (2006) Clin Cancer Res., 12, pp. 6709-6715; Lotz, M.M., Andrews Jr., C.W., Korzelius, C.A., Decreased expression of Mac-2 (carbohydrate binding protein 35) and loss of its nuclear localization are associated with the neoplastic progression of colon carcinoma (1993) Proc Natl Acad Sci USA., 90, pp. 3466-3470; Honjo, Y., Inohara, H., Akahani, S., Expression of cytoplasmic galectin-3 as a prognostic marker in tongue carcinoma (2000) Clin Cancer Res., 6, pp. 4635-4640; Kapucuoglu, N., Basak, P.Y., Bircan, S., Immunohistochemical galectin-3 expression in non-melanoma skin cancers (2009) Pathol Res Pract., 205, pp. 97-103; Vereecken, P., Debray, C., Petein, M., Expression of galectin-3 in primary and metastatic melanoma: Immunohistochemical studies on human lesions and nude mice xenograft tumors (2005) Arch Dermatol Res., 296, pp. 353-358; Vereecken, P., Heenen, M., Serum galectin-3 in advanced melanoma patients: A hypothesis on a possible role in melanoma progression and inflammation (2006) J Int Med Res., 34, pp. 119-120; Iacobini, C., Amadio, L., Oddi, G., Role of galectin-3 in diabetic nephropathy (2003) J Am Soc Nephrol., 14, pp. S264-S270
dcterms.sourceScopus

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
avatar_scholar_256.png
Size:
6.31 KB
Format:
Portable Network Graphics
Description:
Download

Collections

Faculty Of Pharmacy Research Paper